NHS Approves New Treatment for 530 Boys with Duchenne

Around 530 people in England with Duchenne muscular dystrophy will soon benefit from a groundbreaking treatment that could help them walk and maintain independence for years longer than current options allow.

The NHS has approved givinostat, a new medicine available immediately through the Innovative Medicines Fund. This marks the third treatment option for Duchenne, a rare genetic condition that primarily affects boys and progressively destroys muscle strength and function.

Duchenne muscular dystrophy typically appears around age three, when young boys start showing signs of muscle weakness. Without the protein dystrophin to protect their muscles, children gradually lose the ability to walk and stand, become increasingly dependent on caregivers, and face progressive damage to their hearts and lungs.

The new treatment targets patients aged six and over who can still walk or stand, with or without support. Clinical trials show givinostat may extend walking ability by around five years compared to standard care alone, giving families precious extra time together before full mobility loss occurs.

What makes givinostat particularly promising is that it works regardless of the specific genetic type of Duchenne a patient has. The medicine targets the biological processes causing muscle damage and inflammation, protecting muscle function and slowing deterioration in ways current treatments cannot.

Givinostat has already been helping patients since November 2024 through an early access program, giving families a head start before formal approval. The National Institute for Health and Care Excellence accepted higher uncertainty than usual in approving the treatment, recognizing both the severity of Duchenne and the limited options available to families.

The Ripple Effect

The benefits extend beyond the children themselves. By delaying disease progression, givinostat helps reduce complications from muscle deterioration and extends periods when boys can participate in everyday activities with friends and family.

Parents and caregivers also gain valuable time before round-the-clock care becomes necessary. For families watching their sons slowly lose abilities most people take for granted, each additional year of mobility represents countless moments of connection, play, and independence.

Helen Knight, Director of Medicines Evaluation at NICE, praised patient representatives who shared powerful testimony about the devastating impact of Duchenne. She emphasized how givinostat offers "hope where there is currently none" for these families.

The approval demonstrates how the NHS can move quickly when rare diseases demand action, balancing the need for evidence with the urgent reality facing patients who have no time to wait.

With funding secured and immediate access guaranteed, eligible patients across England can start treatment right away while researchers continue gathering long-term data to better understand the full scope of benefits givinostat can provide.